Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503412 | 0.88 | KDM4E (0.39) | KDM4EALDH1A1HRH3CYP2D6CHRM2 | |
| SCHEMBL986268 | 0.81 | HRH3 (0.43) | KDM4EALDH1A1HRH3CYP2D6 | |
| SCHEMBL3272691 | 0.81 | HRH3 (0.40) | KDM4EALDH1A1HRH3CYP2D6CHRM2 | |
| SCHEMBL29866157 | 0.79 | ALDH1A1 (0.41) | KDM4EALDH1A1HRH3 | |
| SCHEMBL29865992 | 0.77 | ALDH1A1 (0.40) | KDM4EALDH1A1HRH3 | |
| SCHEMBL11461060 | 0.77 | CA1 (0.36) | KDM4EALDH1A1CHRM2 | |
| SCHEMBL11470571 | 0.77 | CA1 (0.36) | KDM4EALDH1A1CHRM2 | |
| SCHEMBL1928299 | 0.76 | CHRM4 (0.38) | ALDH1A1HRH3CYP2D6 | |
| SCHEMBL1108992 | 0.76 | CHRM4 (0.38) | ALDH1A1HRH3CYP2D6 | |
| SCHEMBL8487018 | 0.74 | HRH3 (0.32) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | KDM4E 665/4885ALDH1A1 229/4885HRH3 159/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | KDM4E 630/4885ALDH1A1 52/4885HRH3 1028/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | KDM4E 665/4885ALDH1A1 229/4885HRH3 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.